Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 27, 2010
Event Date: December 21, 2010
Context: The company entered into a Share Purchase Agreement with Attara Fund, Ltd. for a private placement of equity securities.
Key Financial Metrics
This filing reports a capital raise transaction rather than operational financial results. Specific metrics include:
- Total Purchase Price: Up to $2,000,000 in cash.
- Shares Offered: Up to 6,250,000 shares of common stock.
- Warrants Offered: Warrants to purchase up to 2,187,500 shares.
- Unit Price: $0.32 per unit (one share plus a warrant for 0.35 shares).
- Warrant Exercise Price: $0.50 per share.
- Warrant Term: Five years from closing.
- Transaction Fees: No underwriting fees or commissions.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, existing debt, or liquidity positions.
Material Changes
The primary material change is the execution of a definitive agreement to raise capital. The transaction is subject to a post-closing limit where the investor cannot hold more than 9.9% of the corporation's outstanding shares. The closing is expected to occur in January 2011.
Guidance, Outlook, and Risks
Outlook: The company anticipates closing the private placement in January 2011.
Risks/Contingencies: The sale of units is not registered under the Securities Act of 1933 and is exempt under Section 4(2) and Rule 505 of Regulation D. The transaction is limited to an "accredited investor."
Investor Verification Checklist
- Confirm the actual closing date of the transaction (expected January 2011).
- Verify the final number of shares and warrants issued, as the agreement allows for "up to" specific amounts subject to the 9.9% ownership cap.
- Review subsequent filings to confirm the receipt of the $2,000,000 cash proceeds.
- Check for any adjustments to the warrant exercise price or term.